meta:
  schema_version: '1.0'
  compatible_engine: cellswarm>=2.0
drug_id: ido_inhibitor
generic_name: Epacadostat
brand_name: N/A
drug_class: immunomodulator
subclass: IDO1_inhibitor
molecular_type: small_molecule
fda_status: investigational
approved_indications: []
targets:
- name: IDO1
  gene: IDO1
  type: enzyme
  action: inhibitor
  selectivity: high
cell_effects:
  CD8_T:
    direct: false
    state_effects:
    - parameter: activation
      direction: increase
      rate_per_step: 0.04
    - parameter: energy
      direction: increase
      rate_per_step: 0.03
    notes: Restores tryptophan availability for T cells
  Tumor:
    direct: true
    state_effects:
    - parameter: immune_evasion
      direction: decrease
      rate_per_step: 0.05
    notes: IDO1 expressed by tumor cells for immune evasion
  Treg:
    direct: false
    state_effects:
    - parameter: suppressive_activity
      direction: decrease
      rate_per_step: 0.04
    notes: Kynurenine promotes Treg differentiation
  Macrophage:
    direct: false
    state_effects:
    - parameter: polarization
      direction: decrease
      rate_per_step: 0.02
  NK:
    direct: false
    state_effects:
    - parameter: activation
      direction: increase
      rate_per_step: 0.03
  B_cell:
    direct: false
    state_effects: []
environment_effects: []
pharmacokinetics:
  administration: oral
  standard_dose: 100 mg BID
  onset_steps: 1
  peak_steps: 1
  half_life_steps: 0.5
  concentration_curve: exponential_decay
  steady_state_fraction: 0.7
dose_response:
  model: hill
  ec50: 0.5
  hill_coefficient: 1.5
  max_effect: 0.75
cancer_specific_modifiers:
  TNBC:
    efficacy_modifier: 0.5
    notes: IDO1 expressed in TNBC
  Melanoma:
    efficacy_modifier: 0.4
    notes: ECHO-301 failed as monotherapy
  NSCLC:
    efficacy_modifier: 0.4
    notes: Investigational
  CRC-MSI-H:
    efficacy_modifier: 0.3
    notes: Limited data
  CRC-MSS:
    efficacy_modifier: 0.4
    notes: IDO1 in immunosuppressive TME
  Ovarian:
    efficacy_modifier: 0.5
    notes: IDO1 high in ovarian TME
resistance:
- mechanism: TDO2 compensatory tryptophan catabolism
  onset_steps: 10
  probability: 0.2
references:
- description: 'ECHO-301: Epacadostat+Pembro in melanoma. Long et al. Lancet Oncol 2019'
  pmid: '31221619'
  verified: true
